Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04680715 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Per-Operative Radiotherapy by Papillon +TM in Localized Breast Cancer

Study acronym: RPOS+2
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site contacts updated at 2 of 2 sitesv8
  2. Phase: Not applicable to Phase 2
    • Site contacts updated at 2 of 2 sites
    v7
  3. 2 versions Re-verified since Jul 22, 2022, no change to tracked fieldsv5-v6
  4. Start date changed from estimate of Sep 2021 to Jul 16, 2021v4
  5. Start date: May 2021 to Sep 2021v3
  6. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Start date: Mar 2021 to May 2021
    • Study sites: 0 to 2
    • Primary completion date: Apr 2027 to Jun 2027
    • Study completion date: Apr 2028 to Jun 2028
    • Eligibility criteria revised
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Phase II study; open recruitment, multicentrique. The aim of this clinical research is to evaluate faisability and toxicity of the per-operative radiotherapy using PAPILLON + TM device for localized breast cancers patients over 65 years.
Trial Details
NCT Number NCT04680715
Lead Sponsor Centre Antoine Lacassagne
Conditions
(from sponsor)		 Localized Breast Cancer
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov